Quantcast

Latest Prostate cancer Stories

2014-07-22 08:31:31

"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program"- Dr. Craig Dionne, CEO SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and...

2014-07-17 23:08:44

Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program. Hollywood, Fla. (PRWEB) July 17, 2014 Mark Soloway, MD, an internationally recognized leader in urologic oncology, has joined the Memorial Cancer Institute and the Memorial Physician Group. Dr. Soloway, who has been appointed Chief of Urologic Oncology, will lead a...

2014-07-16 23:10:21

For the first time ever, Prostate cancer patients can complete a survey describing how their diagnosis changed their lives. New York, NY (PRWEB) July 16, 2014 Prostate cancer disrupts men's lives in ways that are unimaginable. Now, for the first time ever, a national survey is asking men to describe their experiences regarding life after Prostate Cancer diagnosis. The National Men's Cancer Survivor support and advocacy nonprofit, Malecare Cancer Support, designed and launched...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-15 14:06:51

University of Texas M. D. Anderson Cancer Center Wide variations seen in up-front therapy versus active surveillance New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result. The findings, published in JAMA Internal Medicine, sought to examine why active...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...

2014-07-11 09:19:30

Harvard School of Public Health Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the increased risk of lethal cancer cannot be explained by diagnostic bias. It is the largest and most comprehensive study to date to look at the...

2014-07-10 08:27:12

Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to exceed $2 billion by 2015 PETACH TIKVA, Israel, July 10, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli...

2014-07-10 08:26:11

Tenacious Lung Cancer Survivor Fights for Her Life and the Lives of Others WASHINGTON, July 10, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation announces Bonnie J. Addario, a tenacious lung cancer survivor and advocate, as the July LUNGevity Hero for her work in raising awareness of the disease and funds for lifesaving lung cancer research, especially for early detection methods. In late 2003, Bonnie saw her primary care physician and a neurosurgeon about sharp pain on the left side of...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.